Learning the noise fingerprint of quantum devices

Noise sources unavoidably affect any quantum technological device. Noise's main features are expected to strictly depend on the physical platform on which the quantum device is realized, in the form of a distinguishable fingerprint. Noise sources are also expected to evolve and change over time. Here, we first identify and then characterize experimentally the noise fingerprint of IBM cloud-available quantum computers, by resorting to machine learning techniques designed to classify noise distributions using time-ordered sequences of measured outcome probabilities.Comment: 20 pages, 3 figures, 5 tables, research articl

Noise fingerprints in quantum computers: Machine learning software tools

In this paper we present the high-level functionalities of a quantum-classical machine learning software, whose purpose is to learn the main features (the fingerprint) of quantum noise sources affecting a quantum device, as a quantum computer. Specifically, the software architecture is designed to classify successfully (more than 99% of accuracy) the noise fingerprints in different quantum devices with similar technical specifications, or distinct time-dependences of a noise fingerprint in single quantum machines.Comment: 9 pages, 2 figure

Pathological Complete Response to Pembrolizumab plus Axitinib Combination following Serious Immune-Related Adverse Events in an Advanced Renal Cell Carcinoma Patient with a History of Rheumatoid Arthritis

Immune checkpoint inhibitors (ICIs)-based combinations have improved survival outcomes of advanced renal cell carcinoma (RCC) patients and are currently recommended as first-line treatment options. Rheumatoid arthritis (RA) is a systemic autoimmune disease (AD) of unknown etiology characterized by a chronic inflammatory process involving joints and extra-articular organs. Patients with AD are usually excluded from large randomized clinical trials investigating immunotherapeutic drugs. Therefore, little is known about clinical outcomes of patients with a history of RA treated with ICIs in real-world practice. In the present study, we report the clinical outcome of an advanced RCC patient with a history of RA treated with pembrolizumab in combination with axitinib. The patient experienced serious immune-related adverse events (irAEs) and achieved pathological complete response following only one ICI administration. Our case report shows that ICI-based combinations can be administered efficaciously in advanced RCC patients with a history of AD. However, a close monitoring of these patients is required, given the risk of irAEs and clinical exacerbations of symptoms associated with the preexisting AD. Moreover, prospective clinical data are needed to assess the hypothesis of a correlation between the onset of irAEs and AD flares and responses and survival outcomes to ICIs

Kabat rehabilitation for Bell's palsy in the elderly.

CONCLUSIONS: This study has confirmed the importance of combining the physical rehabilitation to the steroid treatment for a better outcome from BP in all age groups, especially in the old HB grade V. OBJECTIVES: To investigate the role played by aging in the recovery rate from peripheral facial nerve palsy. METHOD: In the present study, subjects affected by peripheral facial nerve palsy, distributed by age, were randomly assigned to medical treatment, either alone or associated with Kabat physical rehabilitation. Rate and speed of recovery were assessed in the younger and older groups. All the patients were also asked to fill in a specific questionnaire (beta FAce scale). A series of non-parametric tests (McNemar Chi-square and Chi-square) have been applied to verify the hypothesis of dependence of the final recovery level from the variables age and rehabilitation. RESULTS: The results show that, when treated only by medical therapy, the HB V subjects showed no significant age difference in relation to the achievement of a HB Grade III (100% in the over 65, 80% in the under 65), whilst, in the HB IV subjects, the younger population showed a better recovery, with 89% of a good recovery (HB I or II). In the patients who received the combined protocol, a better recovery rate was found, both in HB IV and V subjects, and the younger population could reach a good recovery in 90% of HB V cases in respect to the older population (50%)